Horizon Therapeutics Public Limited Company
Simbol: HZNP
NASDAQ
116.3
USDTržna cena danes
62.1155
Razmerje P/E
0.5721
Razmerje PEG
26.63B
Kapaciteta MRK
- 0.00%
Donos DIV
Horizon Therapeutics Public Limited Company (HZNP) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 9289.14 | 2352.8 | 1580.3 | 2079.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.net-receivables | 2670.21 | 676.3 | 632.8 | 659.7 | |||||||||||||||
balance-sheet.row.inventory | 694.64 | 169.6 | 225.7 | 75.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 1549.86 | 449.3 | 360.9 | 255.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 14589.66 | 3652.8 | 2799.8 | 3070.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1376.4 | 340.5 | 292.3 | 189 | |||||||||||||||
balance-sheet.row.goodwill | 4042.15 | 1010.5 | 1066.7 | 413.7 | |||||||||||||||
balance-sheet.row.intangible-assets | 13725.2 | 3474.8 | 3840.1 | 1783 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17767.35 | 4485.3 | 4906.8 | 2196.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 1842.66 | 431.8 | 538.1 | 560.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 858.6 | 204.1 | 140.7 | 55.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21845.01 | 5461.8 | 5878 | 3002.2 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.account-payables | 350.07 | 155.8 | 30.1 | 37.7 | |||||||||||||||
balance-sheet.row.short-term-debt | 64 | 16 | 16 | 0 | |||||||||||||||
balance-sheet.row.tax-payables | 172.07 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 10181.67 | 2546.8 | 2555.2 | 1003.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1263.5 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 3198.24 | 777.3 | 840.4 | 838 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12309.97 | 3093.3 | 3118.8 | 1171.5 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 15922.29 | 4042.4 | 4005.3 | 2047.3 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.09 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | 2612.75 | 590 | 318.6 | -215.9 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 48.28 | 12.5 | -15 | -0.1 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17851.26 | 4469.6 | 4368.8 | 4241.4 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 36434.67 | - | - | - | |||||||||||||||
Total Investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.total-debt | 10245.67 | 2562.8 | 2571.2 | 1003.4 | |||||||||||||||
balance-sheet.row.net-debt | 986.05 | 210 | 990.9 | -1076.5 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 438 | 521.5 | 534.5 | 389.8 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 389 | 390.4 | 353.8 | 279.5 | |||||||||||||||
cash-flows.row.deferred-income-tax | -39.11 | 49.8 | -101 | -33.5 | |||||||||||||||
cash-flows.row.stock-based-compensation | 208.04 | 182.1 | 219.1 | 146.6 | |||||||||||||||
cash-flows.row.change-in-working-capital | -5.32 | -12 | -61.7 | -345.7 | |||||||||||||||
cash-flows.row.account-receivables | -44.08 | -43.5 | 34.8 | -251.2 | |||||||||||||||
cash-flows.row.inventory | 33.32 | 56.1 | 1.3 | -21.5 | |||||||||||||||
cash-flows.row.account-payables | 63.98 | 122.2 | -12.2 | 16 | |||||||||||||||
cash-flows.row.other-working-capital | -58.54 | -146.9 | -85.6 | -89.1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 50.03 | 126 | 90.7 | 118.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1040.64 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.acquisitions-net | 28.45 | -3.1 | -2845.3 | -262.3 | |||||||||||||||
cash-flows.row.purchases-of-investments | -8.57 | -9.2 | -24.7 | -13.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.22 | 4.6 | -49.6 | -30 | |||||||||||||||
cash-flows.row.other-investing-activites | -28.45 | 0 | 51.6 | 41.4 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -142.87 | -134 | -2994.1 | -464.1 | |||||||||||||||
cash-flows.row.debt-repayment | -16 | -16 | -12 | -1.7 | |||||||||||||||
cash-flows.row.common-stock-issued | 34.99 | 30.3 | 0 | 919.8 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -250.08 | -250.1 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | -103.35 | -112.2 | 1482.1 | -13.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -334.43 | -348 | 1470.1 | 904.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 8.77 | -2.5 | -10.6 | 7.2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 572.11 | 773.4 | -499.3 | 1003.4 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 9278.67 | 2357.6 | 1584.2 | 2083.5 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 8706.56 | 1584.2 | 2083.5 | 1080 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1040.64 | 1257.8 | 1035.3 | 555.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.free-cash-flow | 906.13 | 1131.6 | 909.1 | 355.8 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3644.41 | 3629 | 3226.4 | 2200.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 903.44 | 920.2 | 794.5 | 532.7 | |||||||||||||||
income-statement-row.row.gross-profit | 2740.97 | 2708.8 | 2431.9 | 1667.7 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 515.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 770.1 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 2173.34 | 1979 | 1878.4 | 1182.6 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 3076.78 | 2899.2 | 2672.9 | 1715.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 441.47 | 497.2 | 365.9 | 278 | |||||||||||||||
income-statement-row.row.ebitda-caps | 957.03 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 513.37 | 617.4 | 543.1 | 490 | |||||||||||||||
income-statement-row.row.income-before-tax | 443.86 | 526.9 | 462.8 | 401.6 | |||||||||||||||
income-statement-row.row.income-tax-expense | 5.86 | 5.5 | -71.7 | 11.8 | |||||||||||||||
income-statement-row.row.net-income | 438 | 521.5 | 534.5 | 389.8 |
Pogosto zastavljeno vprašanje
Kaj je Horizon Therapeutics Public Limited Company (HZNP) skupna sredstva?
Horizon Therapeutics Public Limited Company (HZNP) skupna sredstva so 9114616000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 1777018000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.752.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 3.873.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.120.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.141.
Kaj je Horizon Therapeutics Public Limited Company (HZNP) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 521482000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 2562837000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 1979014000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 2464623000.000.